CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity

Blood

Volumn 118, Issue 14, 2011, Pages 3922-3931

  Sakakibara, Keiichi ^a   Saito, Naoya ^a   Sato, Takuji ^a   Suzuki, Atsushi ^a   Hasegawa, Yoko ^a   Friedman, Jonathan M ^a   Kufe, Donald W ^b   VonHoff, Daniel D ^c   Iwami, Tadahiko ^a   Kawabe, Takumi ^a  

^a CanBas Co Ltd   (Japan)

^b HARVARD MEDICAL SCHOOL   (United States)

^c TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CBS 9106; EXPORTIN 1; I KAPPA B ALPHA; LEPTOMYCIN B; PROTEASOME; PROTEIN INHIBITOR; STREPTAVIDIN; UBIQUITIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE ARREST; CONTROLLED STUDY; DRUG BINDING; MALE; MASS SPECTROMETRY; MOUSE; MULTIPLE MYELOMA; NONHUMAN; NUCLEAR EXPORT SIGNAL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; TUMOR XENOGRAFT; WEIGHT REDUCTION;

EID: 80053619765     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-01-333138     Document Type: Article

References (35)

1. Macara IG. Transport into and out of the nucleus. Microbiol Mol Biol Rev. 2001;65(4):570-594. (Pubitemid 33123518)
2. Yashiroda Y, Yoshida M. Nucleo-cytoplasmic transport of proteins as a target for therapeutic drugs. Curr Med Chem. 2003;10(9):741-748. (Pubitemid 36443230)
3. Turner JG, Sullivan DM. CRM1-mediated nuclear export of proteins and drug resistance in cancer. Curr Med Chem. 2008;15(26):2648-2655.
4. Taagepera S, McDonald D, Loeb JE, et al. Nuclear-cytoplasmic shuttling of C-ABL tyrosine kinase. Proc Natl Acad Sci U S A. 1998;95(13):7457-7462. (Pubitemid 28293274)
5. Vigneri P, Wang JY. Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat Med. 2001;7(2):228-234. (Pubitemid 32148491)
6. Kancha RK, Von Bubnoff N, Miething C, Peschel C, Götze KS, Duyster J. Imatinib and leptomycin B are effective in overcoming imatinib-resistance due to Bcr-Abl amplification and clonal evolution but not due to Bcr-Abl kinase domain mutation. Haematologica. 2008;93(11):1718-1722.
7. Rodriguez MS, Thompson J, Hay RT, Dargemont C. Nuclear retention of IkBa protects it from signalinduced degradation and inhibits nuclear factor kB transcriptional activation. J Biol Chem. 1999;274(13):9108-9115. (Pubitemid 29164718)
8. Gray LJ, Bjelogrlic P, Appleyard VC, et al. Selective induction of apoptosis by leptomycin B in keratinocytes expressing HPV oncogenes. Int J Cancer. 2007;120(11):2317-2324. (Pubitemid 46642116)
9. Yang JY, Hung MC. A new fork for clinical application: targeting forkhead transcription factors in cancer. Clin Cancer Res. 2009;15(3):752-757.
10. Dey A, Tergaonkar V, Lane DP. Double-edged swords as cancer therapeutics: simultaneously targeting p53 and NF-kappaB pathways. Nat Rev Drug Discov. 2008;7(12):1031-1040.
11. Kudo N, Matsumori N, Taoka H, et al. Leptomycin B inactivates CRM1/exportin 1 by covalent modification at a cysteine residue in the central conserved region. Proc Natl Acad Sci U S A. 1999;96(16):9112-9117. (Pubitemid 29374716)
12. Wach JY, Güttinger S, Kutay U, Gademann K. The cytotoxic styryl lactone goniothalamin is an inhibitor of nucleocytoplasmic transport. Bioorg Med Chem Lett. 2010;20(9):2843-2846.
13. Bonazzi S, Eidam O, Güttinger S, et al. Anguinomycins and derivatives: total syntheses, modeling, and biological evaluation of the inhibition of nucleocytoplasmic transport. J Am Chem Soc. 2010;132(4):1432-1442.
14. Mutka SC, Yang WQ, Dong SD, et al. Identification of nuclear export inhibitors with potent anticancer activity in vivo. Cancer Res. 2009;69(2):510-517.
15. Murakami N, Ye Y, Kawanishi M, et al. New Rev-transport inhibitor with anti-HIV activity from Valerianae Radix. Bioorg Med Chem Lett. 2002;12(20):2807-2810. (Pubitemid 35266738)
16. Van Neck T, Pannecouque C, Vanstreels E, Stevens M, Dehaen W, Daelemans D. Inhibition of the CRM1-mediated nucleocytoplasmic transport by N-azolylacrylates: structure-activity relationship and mechanism of action. Bioorg Med Chem. 2008;16(21):9487-9497.
17. Monovich L, Koch KA, Burgis R, et al. Suppression of HDAC nuclear export and cardiomyocyte hypertrophy by novel irreversible inhibitors of CRM1. Biochim Biophys Acta. 2009;1789(5):422-431.
18. Kau TR, Schroeder F, Ramaswamy S, et al. A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells. Cancer Cell. 2003;4(6):463-476. (Pubitemid 38050043)
19. Newlands ES, Rustin GJ, Brampton MH. Phase I trial of elactocin. Br J Cancer. 1996;74(4):648-649. (Pubitemid 26279064)
20. Suganuma M, Kawabe T, Hori H, Funabiki T, Okamoto T. Sensitization of cancer cells to DNA damage-induced cell death by specific cell cycle G2 checkpoint abrogation. Cancer Res. 1999;59(23):5887-5891. (Pubitemid 30004945)
21. Sha SK, Sato T, Kobayashi H, et al. Cell cycle phenotype-based optimization of G2-abrogating peptides yields CBP501 with a unique mechanism of action at the G2 checkpoint. Mol Cancer Ther. 2007;6(1):147-153. (Pubitemid 46206677)
22. Sturgeon CM, Cinel B, Díaz-Marrero AR, et al. Abrogation of ionizing radiation-induced G2 checkpoint and inhibition of nuclear export by Cryptocarya pyrones. Cancer Chemother Pharmacol. 2008;61(3):407-413. (Pubitemid 350275975)
23. Lane DP, Cheok CF, Lain S. p53-based cancer therapy. Cold Spring Harb Perspect Biol. 2010;2(9):a001222.
24. Shuck-Lee D, Chen FF, Willard R, et al. Heterocyclic compounds that inhibit Rev-RRE function and human immunodeficiency virus type 1 replication. Antimicrob Agents Chemother. 2008;52(9):3169-3179.
25. Hideshima T, Chauhan D, Richardson P, et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem. 2002;277(19):16639-16647. (Pubitemid 34967682)
26. Fornerod M, Van Deursen J, Van Baal S, et al. The human homologue of yeast CRM1 is in a dynamic subcomplex with CAN/Nup214 and a novel nuclear pore component Nup88. EMBO J. 1997;16(4):807-816. (Pubitemid 27089527)
27. Kudo N, Khochbin S, Nishi K, et al. Molecular cloning and cell cycle-dependent expression of mammalian CRM1, a protein involved in nuclear export of proteins. J Biol Chem. 1997;272(47):29742-29751. (Pubitemid 27508069)
28. Turner JG, Marchion DC, Dawson JL, et al. Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition. Cancer Res. 2009;69(17):6899-6905.
29. Goldberg AL. Functions of the proteasome: from protein degradation and immune surveillance to cancer therapy. Biochem Soc Trans. 2007;35(Pt 1):12-17.
30. Jang BC, Paik JH, Jeong HY, et al. Leptomycin B-induced apoptosis is mediated through caspase activation and down-regulation of Mcl-1 and XIAP expression, but not through the generation of ROS in U937 leukemia cells. Biochem Pharmacol. 2004;68(2):263-274.
31. Chauhan D, Auclair D, Robinson EK, et al. Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays. Oncogene. 2002;21(9):1346-1358. (Pubitemid 34214500)
32. Hideshima T, Ikeda H, Chauhan D, et al. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood. 2009;114(5):1046-1052.
33. Quach H, Ritchie D, Stewart AK, et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia. 2010;24(1):22-32.
34. Matsuyama A, Arai R, Yashiroda Y, et al. ORFeome cloning and global analysis of protein localization in the fission yeast Schizosaccharomyces pombe. Nat Biotechnol. 2006;24(7):841-847. (Pubitemid 44086626)
35. Wright JJ. Combination therapy of bortezomib with novel targeted agents: an emerging treatment strategy. Clin Cancer Res. 2010;16(16):4094-4104.